Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
